List of Excipients in Branded Drug RANITIDINE HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing RANITIDINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
NCS HealthCare of KY Inc dba Vangard Labs	ranitidine hydrochloride	0615-1354	AMMONIA
NCS HealthCare of KY Inc dba Vangard Labs	ranitidine hydrochloride	0615-1354	FD&C BLUE NO. 1
NCS HealthCare of KY Inc dba Vangard Labs	ranitidine hydrochloride	0615-1354	FD&C RED NO. 40

What are the Most Frequently-Used Excipients in RANITIDINE HYDROCHLORIDE?

# Of NDCs	Excipient
4	AMMONIA
6	CELLULOSE, MICROCRYSTALLINE
1	COLLOIDAL SILICON DIOXIDE

Ranitidine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

Ranitidine hydrochloride has limited near-term commercial value as a conventional oral drug because FDA-requested withdrawal removed ranitidine products from the U.S. market after NDMA contamination concerns. The strongest opportunity is not a conventional generic launch. It is a tightly controlled reformulation platform built around low-nitrite excipients, impurity-minimizing manufacturing, protective packaging, and validated long-term stability.

The active ingredient’s original composition-of-matter and basic formulation patents have expired. New intellectual-property value would need to come from formulation architecture, impurity control, manufacturing processes, packaging, or a differentiated regulatory pathway. Any commercial program must address both ranitidine degradation and nitrosamine formation throughout the product lifecycle.

What is the FDA regulatory status of ranitidine hydrochloride?

Ranitidine products are not currently marketed in the United States under the FDA’s prior approvals. On April 1, 2020, the FDA requested that all ranitidine products be withdrawn because storage-related increases in NDMA could expose patients to unacceptable levels of the probable human carcinogen. The agency stated that NDMA levels increased over time and at higher storage temperatures (FDA, 2020a).

In 2021, the FDA stated that it had not identified sufficient evidence supporting the safe marketing of ranitidine products in the United States. The agency has continued to recommend alternatives such as famotidine, cimetidine, and proton-pump inhibitors for appropriate patients (FDA, 2021).

Regulatory issue	Status
U.S. marketed ranitidine product	Withdrawn
U.S. prescription and OTC ranitidine	Not commercially available under prior products
Principal safety issue	NDMA formation and contamination
Primary FDA action	April 2020 withdrawal request
Relevant regulatory route for a new product	New NDA, likely involving reformulation and complete quality data
Generic substitution opportunity	Limited without an approved reference product and acceptable market authorization
Biosimilar pathway	Not applicable; ranitidine is a small molecule

The European Medicines Agency also recommended suspension of ranitidine medicines in 2020 after detecting NDMA in ranitidine active substances and finished products (EMA, 2020). Regulatory status outside the United States varies by jurisdiction, but the global commercial position remains constrained.

What excipient strategy can reduce ranitidine NDMA risk?

The principal excipient strategy is to control nitrite and nitrate exposure while limiting water activity, heat exposure, and reactive impurities. Excipients should be selected through supplier-specific impurity testing rather than by compendial name alone.

Low-nitrite excipient selection

Potentially relevant excipient classes include:

• Microcrystalline cellulose
• Low-peroxide, low-nitrite grades of povidone
• Crospovidone with controlled nitrite content
• Croscarmellose sodium with supplier qualification
• Low-moisture mannitol
• Selected calcium phosphate systems
• Low-nitrite film-coating polymers
• Controlled-grade magnesium stearate

The same excipient can show materially different nitrite levels across suppliers, manufacturing sites, and lots. A specification should address nitrite, nitrate, moisture, peroxide value, residual solvents, elemental impurities, and microbial quality where relevant.

The formulation developer should establish a nitrite mass balance covering the active pharmaceutical ingredient, excipients, process water, coating materials, packaging components, and cleaning residues. A nominal excipient specification is insufficient if total nitrosamine formation remains uncontrolled.

Water-activity control

Ranitidine hydrochloride is water soluble, and moisture can accelerate chemical reactions involving the active ingredient and reactive impurities. A low-water-activity tablet or dry solid dosage form is generally more attractive than an aqueous product.

Relevant controls include:

• Low-moisture excipients
• High-barrier blister packaging
• Desiccant-equipped bottles
• Low-humidity manufacturing
• Moisture-controlled granulation
• Reduced aqueous exposure during coating
• Accelerated and long-term stability at multiple temperatures

A direct-compression platform may reduce exposure to water and heat compared with wet granulation. It may also reduce process complexity, although blend uniformity and tablet mechanical properties must be demonstrated.

Antioxidant and scavenger systems

Antioxidants or reactive-impurity scavengers may be evaluated, but they should not be treated as a substitute for nitrite control. The commercial value of such systems would depend on demonstrated reduction of NDMA and other degradation products under real-time and accelerated conditions.

Potential development categories include:

• Chelating agents to control catalytic trace metals
• Antioxidants where compatible with ranitidine hydrochloride
• Reactive-impurity scavengers
• Protective polymer matrices
• Multilayer tablets separating incompatible components

Any scavenger system creates new regulatory questions involving extractables, leachables, tolerability, dose uniformity, and long-term stability.

What ranitidine formulations offer the best commercial opportunity?

Immediate-release tablets

Immediate-release tablets have the clearest development logic because they avoid the high water content of liquids and can use low-moisture excipients. The most defensible formulation concept would combine:

1. A qualified low-nitrite excipient package.
2. Direct compression or a low-water granulation process.
3. Protective film coating.
4. High-barrier packaging.
5. A validated nitrosamine-control strategy.

A new tablet would still require extensive stability data. A reformulated tablet cannot rely solely on the historical safety profile of ranitidine.

Effervescent tablets

Effervescent formulations are commercially less attractive. They contain acid-base systems that can increase moisture sensitivity and may introduce additional reactive impurities. Their formulation may also require more complex packaging and tighter humidity controls.

Oral solutions and syrups

Liquid products present the highest technical risk because water, heat, pH, and storage time can accelerate degradation and NDMA formation. Preservatives and sweeteners may introduce additional nitrite, nitrate, peroxide, or amine impurities.

A liquid could have clinical value for pediatric or dysphagia populations, but its commercial case would require unusually strong stability data and packaging controls. Unit-dose, low-headspace packaging could reduce exposure but would increase manufacturing cost.

Injectable products

Injectable ranitidine products face the most demanding quality standards. The formulation must address sterility, particulate matter, container compatibility, pH, degradation, and nitrosamine risk. The historical injectable market is unlikely to justify development unless a sponsor has a specific institutional or hospital-use strategy.

Modified-release products

Modified-release ranitidine could create patentable technical differentiation, but the underlying clinical demand is weak because multiple established acid-suppression alternatives exist. A modified-release product would need a defined pharmacokinetic or adherence advantage to justify its regulatory and manufacturing cost.

Formulation	NDMA-control profile	Development complexity	Commercial attractiveness
Immediate-release tablet	More manageable	Moderate	Highest among ranitidine options
Capsule	Manageable but shell and fill require testing	Moderate	Moderate
Effervescent tablet	Higher moisture and reactive-system risk	High	Low to moderate
Oral solution	High water-related risk	High	Low
Injection	Very high quality and regulatory burden	Very high	Low
Modified-release tablet	Depends on matrix chemistry	High	Selective

What patents protect ranitidine hydrochloride?

The original ranitidine compound patent estate has expired. The principal U.S. compound patent commonly associated with ranitidine is U.S. Patent No. 4,128,658. Its effective exclusivity ended decades ago under the pre-1995 U.S. patent-term framework, subject to the specific historical term and regulatory adjustments applicable at the time.

Historical formulation and manufacturing patents also expired or lost practical exclusivity. The active ingredient therefore has no meaningful composition-of-matter barrier in the United States.

Current intellectual-property opportunities would be narrower and more technical:

• Low-nitrite excipient combinations
• Specific moisture-control systems
• Nitrosamine-reduction processes
• Packaging configurations
• Solid-state or particle-engineering approaches
• Manufacturing sequences that reduce reactive impurities
• Stability-indicating analytical methods
• New therapeutic uses, where legally available and clinically supported

A patent claiming only “ranitidine hydrochloride with common pharmaceutical excipients” would face substantial novelty and obviousness risks. A stronger application would link a defined excipient impurity profile and manufacturing process to a measured reduction in NDMA formation.

When does ranitidine lose exclusivity?

Ranitidine lost its core U.S. patent exclusivity many years ago. The original generic market developed before the 2020 withdrawal. There is no current originator exclusivity that protects a conventional ranitidine tablet from generic competition.

Exclusivity category	Ranitidine position
Composition-of-matter patent	Expired
Basic oral formulation patents	Generally expired
Historical FDA approval exclusivity	Expired
Current U.S. market exclusivity	None for the withdrawn products
New formulation exclusivity	Potentially available only for a newly approved product
Orphan exclusivity	Not applicable to conventional ranitidine use
Biosimilar exclusivity	Not applicable

A newly approved ranitidine formulation could receive regulatory exclusivity only if it meets the requirements for the applicable FDA pathway. Exclusivity would not restore broad protection for the active ingredient.

What is the Orange Book status of ranitidine?

Historical ranitidine products were associated with FDA-approved NDAs and numerous ANDAs. Zantac was associated with NDA 019128 in FDA historical records. Following withdrawal, the commercial relevance of those listings is limited.

The FDA Orange Book should be reviewed for the status of specific NDA and ANDA entries because withdrawn products, discontinued products, and patent listings can have different database treatment. A withdrawn ranitidine product does not create an active market barrier comparable to a currently marketed reference drug (FDA, n.d.-a).

For a new product, the sponsor would need to determine whether the product is:

• A new NDA based on a reformulated ranitidine product.
• A 505(b)(2) application relying partly on prior findings.
• A different pathway available in a specific jurisdiction.
• A product requiring a new clinical benefit-risk assessment because of the prior NDMA history.

A 505(b)(2) strategy may be difficult if the proposed product materially changes the active ingredient’s impurity profile, exposure, formulation, or clinical risk. The sponsor would need to establish why the new product is safe despite the regulatory history.

Are there Paragraph IV challenges for ranitidine?

Historical generic ranitidine products generated the expected patent-certification and litigation activity associated with an off-patent small molecule. The principal patent disputes are no longer the central commercial issue because the relevant patents expired and the market was withdrawn.

For a future reformulated product, Paragraph IV risk would depend on the patent claims listed for the new reference product. Potential challenges could target:

• Lack of novelty in the excipient combination.
• Obviousness based on known low-nitrite formulation practices.
• Inadequate written description.
• Lack of enablement across the claimed impurity range.
• Failure to demonstrate unexpected results.
• Noninfringement based on different excipient grades or packaging.

A sponsor seeking protection should generate comparative data against conventional ranitidine formulations. Evidence showing lower NDMA formation, longer stability, and reproducible performance across suppliers would improve the defensibility of the patent estate.

How strong is the patent estate for a new ranitidine formulation?

The patent estate is weak for the active ingredient and potentially moderate for a technically specific reformulation. Claim strength will depend on whether the invention is defined by measurable product attributes rather than by generic excipient names.

Stronger claim types

• A defined total nitrite limit across the formulation.
• A specified water-activity range.
• A packaging system that maintains stability under elevated humidity.
• A manufacturing process with controlled thermal exposure.
• A demonstrated NDMA threshold over a defined storage period.
• A specific combination of excipient grade, coating, and container closure.

Weaker claim types

• Broad claims covering all ranitidine tablets.
• Claims using conventional fillers and binders without unexpected results.
• Claims relying only on a lower nominal impurity specification.
• Claims that do not distinguish the product from historical generic formulations.

The best commercial strategy is likely a layered estate covering composition, process, packaging, analytical control, and selected use claims.

What manufacturing and IP barriers affect commercial launch?

The primary barrier is analytical and regulatory, not raw-material availability. A sponsor must control nitrite and nitrate sources across the full supply chain.

Important manufacturing controls include:

• API vendor qualification and lot-release testing.
• Excipient supplier mapping.
• Separate storage of reactive raw materials.
• Water-system monitoring.
• Temperature and humidity controls.
• Low-temperature drying where applicable.
• Container-closure qualification.
• Stability testing through expiry.
• Testing for NDMA and other nitrosamines using validated methods.

The FDA has issued broader guidance on nitrosamine risk management for human drugs, including assessment of drug substances, excipients, manufacturing processes, and packaging (FDA, 2023). Ranitidine would receive close scrutiny because the product’s historical issue was directly linked to NDMA formation during storage.

Which companies are challenging or replacing ranitidine?

No current U.S. generic launch challenge is commercially meaningful because ranitidine products were withdrawn. The competitive set consists of replacement acid-suppression products:

Product class	Representative active ingredients	Competitive position
H2 receptor antagonists	Famotidine, cimetidine	Closest pharmacologic substitutes
Proton-pump inhibitors	Omeprazole, esomeprazole, lansoprazole	Strong OTC and prescription competition
Antacids	Calcium carbonate, magnesium hydroxide, aluminum hydroxide	Low-cost symptom relief
Potassium-competitive acid blockers	Vonoprazan in applicable markets	Newer mechanism and differentiated efficacy

Famotidine is the most direct commercial substitute because it occupies the H2-blocker category without the ranitidine NDMA history. Any ranitidine relaunch would need a clear advantage in cost, tolerability, dosing, or a specific patient population.

What revenue exposure does ranitidine represent?

Ranitidine was historically a major global product. Zantac became one of the first medicines to exceed $1 billion in annual sales, but those revenues were generated before generic erosion and the 2020 withdrawal. Current revenue exposure is therefore primarily historical and litigation-related rather than a continuing branded-sales stream.

Commercial upside from a new ranitidine product is constrained by:

• Loss of prescriber confidence.
• Availability of famotidine and proton-pump inhibitors.
• Regulatory review of NDMA controls.
• Potential litigation and product-liability exposure.
• High stability-testing costs.
• Limited value of the unprotected active ingredient.

The strongest opportunities may involve enabling technologies rather than a standalone ranitidine brand. These include low-nitrite excipient platforms, analytical testing services, high-barrier packaging, and contract development programs for nitrosamine-sensitive products.

What generic launch scenarios exist for ranitidine?

Scenario 1: Conventional generic relaunch

This scenario has the lowest probability of success. A conventional tablet without a differentiated impurity-control strategy would face regulatory resistance and weak market demand.

Scenario 2: Reformulated prescription product

This is more credible if supported by a robust 505(b)(2) or NDA strategy, complete nitrosamine data, and a clinical or safety rationale. The product would need to establish a favorable benefit-risk profile independent of historical ranitidine approvals.

Scenario 3: Hospital or institutional formulation

An injectable or unit-dose product could target a narrow institutional market. The development burden would be high, and famotidine competition would remain substantial.

Scenario 4: Non-U.S. launch

A sponsor could pursue selected markets where ranitidine remains permitted or where local regulatory standards differ. This would not remove the need for NDMA controls. Geographic opportunity is jurisdiction-specific and subject to local suspension, withdrawal, and registration requirements.

What licensing deals could support a ranitidine program?

A licensing strategy would be more attractive for enabling technology than for the ranitidine active ingredient. Potential deal structures include:

• Exclusive rights to a low-nitrite excipient system.
• Access to proprietary nitrosamine analytical methods.
• Co-development with a packaging company.
• Regional licensing of a reformulated product.
• Contract manufacturing with dedicated impurity controls.
• Acquisition of a formulation patent family.

The active ingredient itself is widely available and does not justify a conventional exclusive license. Value would come from a demonstrated formulation advantage supported by patent claims and regulatory data.

Key Takeaways

• Ranitidine hydrochloride has no meaningful remaining core patent exclusivity.
• U.S. ranitidine products were withdrawn after the FDA identified NDMA-related risks.
• Immediate-release, low-moisture tablets offer the most practical formulation opportunity.
• Excipient selection must include supplier-specific nitrite, nitrate, peroxide, moisture, and trace-metal testing.
• High-barrier packaging is part of the formulation strategy, not a secondary commercial feature.
• New IP should focus on measurable impurity control, process conditions, packaging, and stability.
• A conventional generic relaunch is commercially weak.
• Famotidine and proton-pump inhibitors are the principal replacement competitors.
• Biosimilar risk is irrelevant because ranitidine is a small molecule.
• The best licensing opportunities involve excipient platforms, analytical controls, packaging, and manufacturing technology.

FAQs

Can low-nitrite excipients alone make ranitidine commercially viable?

No. Low-nitrite excipients are necessary but not sufficient. The sponsor must control API impurities, water activity, process conditions, packaging, and long-term NDMA formation.

Is ranitidine hydrochloride suitable for an OTC relaunch?

An OTC relaunch would face substantial regulatory and consumer-confidence barriers. It would require a new safety and quality assessment rather than reliance on the historical OTC status of Zantac or generic ranitidine.

Could a new ranitidine formulation receive a new patent?

Yes, but protection would likely be narrow. The strongest claims would cover a defined excipient impurity profile, manufacturing process, packaging system, or demonstrated stability result.

Does ranitidine have biosimilar competition?

No. Biosimilars apply to biological products. Ranitidine hydrochloride is a chemically synthesized small molecule, so the relevant competition is from generics and alternative H2 blockers.

What is the most valuable commercial asset in a ranitidine program?

The most valuable asset is likely a validated nitrosamine-control platform that can be applied to ranitidine and other susceptible drug products. A standalone conventional ranitidine active-ingredient business has limited strategic value.

References

European Medicines Agency. (2020). EMA recommends suspension of all ranitidine medicines in the EU. https://www.ema.europa.eu/

U.S. Food and Drug Administration. (2020a). FDA requests removal of all ranitidine products from the market. https://www.fda.gov/

U.S. Food and Drug Administration. (2021). Questions and answers: NDMA impurities in ranitidine (commonly known as Zantac). https://www.fda.gov/

U.S. Food and Drug Administration. (2023). Control of nitrosamine impurities in human drugs: Guidance for industry. https://www.fda.gov/

U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/‑core/enterprise/search.cfm

U.S. Patent No. 4,128,658. (1978). N-substituted nitroethenediamines. United States Patent and Trademark Office.